Facebook Linkedin RSS Twitter Youtube
Home 2016

Restless legs syndrome

Dr. Reddy’s Acquires U.S. Rights to XenoPort’s Phase III Psoriasis Candidate
Industry News

Dr. Reddy’s Acquires U.S. Rights to XenoPort’s Phase III Psoriasis Candidate

XenoPort and GSK End Horizant Collaboration
News

XenoPort and GSK End Horizant Collaboration

FDA Approves XenoPort, GSK’s Horizant for Managing Postherpetic Neuralgia
Drug Discovery

FDA Approves XenoPort, GSK’s Horizant for Managing Postherpetic Neuralgia

Impax and GSK Report Positive Data from Third Phase III Study with Parkinson Disease Drug
News

Impax and GSK Report Positive Data from Third Phase III Study with Parkinson Disease Drug

XenoPort and GSK’s Treatment for Restless Legs Syndrome Cleared in the U.S.
News

XenoPort and GSK’s Treatment for Restless Legs Syndrome Cleared in the U.S.

Omeros Adds Addiction and Compulsive Disorders to License Agreement with Daiichi
News

Omeros Adds Addiction and Compulsive Disorders to License Agreement with Daiichi

Astellas and XenoPort Submit Japanese Filing for RLS Therapy
News

Astellas and XenoPort Submit Japanese Filing for RLS Therapy

XenoPort Opts into Co-Promotion Deal with GSK for RLS Drug
News

XenoPort Opts into Co-Promotion Deal with GSK for RLS Drug

GSK and XenoPort Are Temporarily Withdrawing Their RLS NDA
News

GSK and XenoPort Are Temporarily Withdrawing Their RLS NDA

XenoPort Shares Spike on Successful Phase III RLS Trial
News

XenoPort Shares Spike on Successful Phase III RLS Trial

12Page 1 of 2
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.